RDi is the UK’s leading automated, data-led healthcare fulfilment specialist.

Investment type
  • Management buyout

Delivering business expansion

Since LDC’s investment, RDi has expanded significantly, bolstering the senior team and increasing headcount from 82 to 130. Revenues have increased from £18m to £25m, and healthcare as a proportion of core business has shifted from 22% to over 70%.

RDi’s rapid growth has been accelerated by the successful acquisition of diagnostic sample collection and transport packaging provider MedDX in 2022, and of biological sample packaging provider Shuttlepac in 2023. Both acquisitions have significantly broadened RDi’s portfolio of healthcare kitting and component capabilities, enabling it to better serve the evolving needs of its customers as well as creating greater visibility and control over RDi’s supply chains and attracting a broader portfolio of customers.

RDi is well positioned to take advantage of the phenomenal global interest in healthcare screening, testing and monitoring as early-detection continues to rise up the agenda of individuals, companies and governments. The business is expanding into the US market, the largest market in the world for home-testing kits.

The business is also highly focused on sustainability, and on reducing the use of plastics by
minimising the size of its kits, components and packaging.

Quote mark

When it came to the acquisitions, LDC provided a framework to facilitate the integration of these businesses, which was hugely beneficial. It can be daunting going into an acquisition for the first time, especially during a period of rapid growth, but LDC’s experience reassured us and really helped to accelerate our journey.”

Chris Tagg, Chief Strategy Officer